journal article·2026-03

Inhaled biomimetic nanoparticles enhance pulmonary delivery of tetrandrine and pirfenidone for the treatment of idiopathic pulmonary fibrosis

Xinrui Zhang, Ruibing Yu, Xusheng Duan, Tenghan Zhang, Fanyu Cheng, Shan Pan, Dongfang Zhou, Juhong Zhu, Yue Cai, Xuanrong Sun

Acta Biomaterialia· Volume 212
Publisher page

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease marked by epithelial-mesenchymal transition (EMT) and overactivation of the transforming growth factor-β (TGF-β) signaling pathway, leading to collagen accumulation and macrophage infiltration in the lungs. Here, a bioinspired inhalable nanoplatform (PCMΦ@PPT) was designed and prepared for delivering therapy agents by penetrating the excessive physiological barrier deposited in the lesions and reversing established fibrotic foci in IPF. The nanoplatform was composed of two components: a pirfenidone (PFD) and tetrandrine (TET) co-loaded poly(lactic-co-glycolic acid) (PLGA) core (PPT), as well as a collagen-binding peptide and collagenase functionalized macrophage membrane (PCMΦ) shell. Following inhalation, PCMΦ@PPT has been shown to possess the capacity to target and penetrate the dense collagen barrier with the assistance of functional groups present on PCMΦ. The coating of PCMΦ enables PCMΦ@PPT to evade phagocytosis by macrophages that accumulate at the site of lesions. Meanwhile, the precise co-delivery of PFD and TET to the lesion site not only blocks the TGF-β signaling pathway but also promotes the recovery of damaged autophagy in fibroblasts, thereby alleviating the progression of IPF and partially improved lung function parameters of mice. In summary, this study proposes a novel nano-inhalation formulation for the treatment of IPF. STATEMENT OF SIGNIFICANCE: The biomimetic nanoparticle PCMΦ@PPT was designed to recognize and degrade overexpressed extracellular matrix proteins. It is composed of two components: a poly(lactic-co-glycolic acid) core co-loaded with pirfenidone (PFD) and tetrandrine (TET), as well as a collagen-binding peptide and collagenase-functionalized macrophage membrane shell (PCMΦ). Following inhalation, PCMΦ@PPT has been shown to target and penetrate the dense collagen barrier while evading phagocytosis by macrophages, promoting drug retention in the focus. Finally, co-delivery of PFD and TET blocks the TGF-β signaling pathway, promoting recovery of damaged autophagy in fibroblasts and alleviating IPF progression and restoring lung function.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Inhalation and Respiratory Drug Delivery · Neonatal Respiratory Health Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (57)

Show source-provided references
1. Idiopathic pulmonary fibrosis: disease mechanisms and drug development10.1016/j.pharmthera.2020.107798 ↗
2. Idiopathic pulmonary fibrosis: an update on pathogenesis
3. Idiopathic pulmonary fibrosis: current and future treatment10.1111/crj.13466 ↗
4. Epigenetics of idiopathic pulmonary fibrosis10.1016/j.trsl.2014.03.011 ↗
5. Precision medicine advances in idiopathic pulmonary fibrosis10.1016/j.ebiom.2023.104766 ↗
6. The role of autophagy in idiopathic pulmonary fibrosis: from mechanisms to therapies10.1177/17534666221140972 ↗
7. Idiopathic pulmonary fibrosis10.1016/S0140-6736(11)60052-4 ↗
8. The therapy of idiopathic pulmonary fibrosis: what is next?10.1183/16000617.0021-2019 ↗
9. Daphnetin alleviates bleomycin-induced pulmonary fibrosis through inhibition of epithelial-to-mesenchymal transition and IL-17A10.3390/cells12242795 ↗
10. Current and future treatment landscape for idiopathic pulmonary fibrosis10.1007/s40265-023-01950-0 ↗
11. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways10.1186/s10020-020-00173-3 ↗
12. Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways10.1016/j.ecoenv.2022.114066 ↗
13. Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model10.1038/s41467-023-36314-5 ↗
14. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis10.1056/NEJMoa1402582 ↗
15. Tetrandrine - a molecule of wide bioactivity10.1016/j.phytochem.2016.02.005 ↗
16. Natural products as multidrug resistance modulators in cancer10.1016/j.ejmech.2019.05.027 ↗
17. Tetrandrine: a review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems10.1111/jphp.13339 ↗
18. Progress on structural modification of tetrandrine with wide range of pharmacological activities10.3389/fphar.2022.978600 ↗
19. Tetrandrine alleviates inflammation and promotes macrophage M2 polarization in gouty arthritis by NF-κb-mediated Lcp110.14715/cmb/2024.70.2.29 ↗
20. Tetrandrine suppresses articular inflammatory response by inhibiting pro-inflammatory factors via NF-κb inactivation10.1002/jor.23155 ↗
21. Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases
22. Inhalation of tetrandrine-hydroxypropyl-β-cyclodextrin inclusion complexes for pulmonary fibrosis treatment10.1021/acs.molpharmaceut.0c00026 ↗
23. Tetrandrine ameliorates collagen-induced arthritis in mice by restoring the balance between Th17 and treg cells via the aryl hydrocarbon receptor10.1016/j.bcp.2015.11.025 ↗
24. Tetrandrine induces lipid accumulation through blockade of autophagy in a hepatic stellate cell line10.1016/j.bbrc.2016.06.018 ↗
25. Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis10.1152/ajpheart.00126.2015 ↗
26. Tetrandrine, an activator of autophagy, induces autophagic cell death via PKC-α inhibition and mTOR-dependent mechanisms10.3389/fphar.2017.00351 ↗
27. Oral inhalation for delivery of proteins and peptides to the lungs10.1016/j.ejpb.2021.04.003 ↗
28. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis10.1038/s41467-020-15647-5 ↗
29. Cellular metabolomics of pulmonary fibrosis, from amino acids to lipids10.1152/ajpcell.00586.2020 ↗
30. Macrophage implication in IPF: updates on immune, epigenetic, and metabolic pathways10.3390/cells12172193 ↗
31. Molecular imaging of fibrosis using a novel collagen-binding peptide labelled with 99mTc on SPECT/CT10.1007/s00726-016-2328-7 ↗
32. Intracellular MRSA-targeted lipid-polymer hybrid nanoparticles for macrophage reprogramming and intracellular MRSA eradication10.1016/j.cej.2025.159665 ↗
33. Mucus adhesion vs. mucus penetration? Screening nanomaterials for nasal inhalation by MD simulation10.1016/j.jconrel.2022.11.051 ↗
34. Cleavable collagenase-assistant nanosonosensitizer for tumor penetration and sonodynamic therapy10.1016/j.biomaterials.2022.121992 ↗
35. Surface functionalization of exosomes for chondrocyte-targeted siRNA delivery and cartilage regeneration10.1016/j.jconrel.2024.04.009 ↗
36. A collagenase-decorated cu-based nanotheranostics: remodeling extracellular matrix for optimizing cuproptosis and MRI in pancreatic ductal adenocarcinoma10.1186/s12951-024-02968-6 ↗
37. Validation of a rapid collagenase activity detection technique based on fluorescent quenched gelatin with synovial fluid samples10.1186/s12896-024-00869-y ↗
38. Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy10.1016/j.jconrel.2022.09.054 ↗
39. Macrophages: friend or foe in idiopathic pulmonary fibrosis?10.1186/s12931-018-0864-2 ↗
40. Pulmonary macrophages: key players in the innate defence of the airways10.1136/thoraxjnl-2015-207020 ↗
41. Fibroblast to myofibroblast transition is enhanced by increased cell density10.1091/mbc.E20-08-0536 ↗
42. m6A modification regulates lung fibroblast-to-myofibroblast transition through modulating KCNH6 mRNA translation10.1016/j.ymthe.2021.06.008 ↗
43. The myofibroblast in pulmonary fibrosis*10.1378/chest.122.6_suppl.286S ↗
44. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis10.1016/j.jhep.2020.04.044 ↗
45. Autophagy activates EGR1 via MAPK/ERK to induce FGF2 in renal tubular cells for fibroblast activation and fibrosis during maladaptive kidney repair10.1080/15548627.2023.2281156 ↗
46. ATF3 -activated accelerating effect of LINC00941/lncIAPF on fibroblast-to-myofibroblast differentiation by blocking autophagy depending on ELAVL1/HuR in pulmonary fibrosis10.1080/15548627.2022.2046448 ↗
47. Tetrandrine inhibits skeletal muscle differentiation by blocking autophagic flux10.3390/ijms23158148 ↗
48. Genetic associations and lung function in IPF: unexpected answers, persistent questions10.1016/S2213-2600(22)00270-3 ↗
49. ISABELA 1 and 2 Investigators, Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials10.1001/jama.2023.5355 ↗
50. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge10.1126/sciadv.abn7162 ↗
51. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis10.1007/s00228-024-03720-7 ↗
52. Animal studies on medicinal herbs: predictability, dose conversion and potential value10.1002/ptr.4966 ↗
53. Pirfenidone Clinical Study Group in Japan, Pirfenidone in idiopathic pulmonary fibrosis10.1183/09031936.00005209 ↗
54. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung10.1172/jci.insight.96352 ↗
55. Evaluation of a method for assessing respiratory mechanics during noninvasive ventilation10.1034/j.1399-3003.2000.16d23.x ↗
56. Idiopathic pulmonary fibrosis10.1016/S0140-6736(17)30866-8 ↗
57. PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation10.1016/j.phrs.2022.106636 ↗